drug · small molecule
sevasemten
Phase 3updated 3mo agoby $EWTX Edgewise Therapeutics, Inc.🔗 ChEMBL
Phase 3community read0 votes
Small molecule drug with a maximum clinical stage of Phase 2 (across all indications), with 3 investigational indications.
indications
indications
Duchenne Muscular Dystrophy
all catalysts(0)
nothing on the calendar yet
Trials studying sevasemten
- phase2Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
- phase2Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
- phase2A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)
- phase2Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy
- phase1A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy
- phase1A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers
News(2)
- Servier buys into muscular dystrophy with potentially $2.7B dealThe French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say could eventually hit peak sales of over $2 billion.biopharma_dive · 2mo ago
- STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drugThe French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.stat · 2mo ago
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that